Personalized cancer vaccines and TCR-T cell treatments can target this patient. The affinity-improved TCR may also be utilized to target cancer cells that express KRAS G12D by fusing it to a humanized anti-CD3 scFv. The gene discussed is KRAS; the disease is cancer.